RLFTF is a public company with a drug, which is its only asset, that is less than a month away from potential approval. If anything looks like it's shortchanging the investors, the regulatory bodies would be down on them in a minute. Merging out RLFTF is almost a lose-lose deal for them if they acquire a public company like this. NeruoRx is private and can do whatever it wants. Meanwhile, I'm not worried about it.

While anything can happen, the evidence is compelling that the drug works. The efficacy of the drug is the issue. The rest are side shows. I